Indian Biotechnology Company "Biocon" has launched a therapeutic drug to block Epidermal Growth Factor Receptor (EGFR) that reproduces cancer cells.
The Leading Biotechnology Company "Biocon" has launched a therapeutic monoclonal antibody-based drug 'BIOMAb-EGFR' care for rock-hard tumors of epithelial origin, such as neck and head cancers. This newly launched drug is particularly aimed to block Epidermal Growth Factor Receptor (EGFR) that reproduces cancer cells.
All over India "BIOMAb-EGFR" will be obtainable as an item carton of 4 vials. The medicine is the foremost of its type to be clinically enrooted in India. It's the initial anti-EGFR humanized monoclonal antibody for cancer treatment, which would be commercialize globally.
As per the company spokesman, the medicine has shown good response in medical trials, which is initiated in India and worldwide. They also added that the medicine would be produced at the Biocon Park.
The CMD of Biocon said that the price for the drug would be fixed in the coming week, which will be at least 40 percent cheaper than other MNC's of its kind. He also added that the launch of this drug leads Biocon's foray into proprietary immunotherapeutics and the company globally joined special group of monoclonal antibody developers.
Its said, 'BIOMAb-EGFR' symbolizes Biocon's huge investment up till now for the advancement of this medicine. Biocon has initiated talks with several nations for authorization and plans to make the drug available in the US and Europe.
Related Market Research Reports:
Asia Pacific Biotechnology Market (2008-2012)
Booming Biotech Market in India
Global Cancer Treatment Forecast to 2012
